CBD: Wonder Drug of the Future
DOI:
https://doi.org/10.37591/rrjon.v7i1.962Abstract
The traditional “wonder drug” in pharmacology is aspirin, well known for its properties of pain control, lowering elevated body temperature, fighting inflammation, and decreasing blood coagulation. Aspirin, as a non-steroidal anti-inflammatory drug (NSAID) is a preventative drug as well as a therapeutic one. The Framingham heart study has concluded that a low dose aspirin regimen (81 mg/day) will help prevent cardiovascular disease and stroke. On the other hand, CBD (cannabidiol) may be designated the “wonder drug” of the future! CBD, a major extract of most strains of cannabis has a broad-spectrum of pharmacological properties including anxiolytic, anticompulsive, antipsychotic, neuroprotective, analgesic, anti-emetic, antispasmodic, anti-inflammatory, anti-neoplastic, and the lowering of intraocular pressure. CBD has potential applications in medical therapy for diverse conditions including anxiety-related disorders, psychogenic disorders, glaucoma, epilepsy, migraine headaches, Crohn’s disease, cancer chemotherapy, and HIV/AIDS. CBD is non-toxic and safe to most body systems whereas even moderate doses of aspirin can be ulcerative to the stomach and toxic to the kidneys.
Keywords: Cannabidiol, CBD, cannabis, aspirin, anxiety disorders, OCD, aspirin
Cite this Article
Flaer Paul J. CBD: “Wonder Drug” of the Future. Research & Reviews: Journal of Neuroscience. 2017; 7(1): 1–5p.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
